The pancreatic cancer with highly unmet medical needs may welcome a newly listed drug.

The pharmaceutical industry sources reported Servier Korea’s Onivyde (Irinotecan Hydrochloride) would be deliberated by the Health Insurance Review and Assessment Service (HIRA) Drug Reimbursement Evaluation Committee (DREC). Requested for the National Health Insurance (NHI) reimbursement last July, the drug is finally starting the practical discussion on the listing after about six months.

Onivyde has requested for reimbursement on an indication to treat patients, who have failed a first-line gemcitabine-based treatment, as second-line 5-FU/LV combination therapy.

But Onivyde faces